Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease
Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease
Search
Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support
Burlington, ON (October 25, 2023) – In a unique partnership, Boehringer Ingelheim (Canada) Ltd., St. Joseph's Healthcare Hamilton, and McMaster University have come together to transform the way patients are supported at the onset of a diagnosis
Tackling care gaps in respiratory diseases in Alberta
Tackling care gaps in respiratory diseases in Alberta
Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario
Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario
New health projects empower Indigenous communities to address chronic diseases
New health projects empower Indigenous communities to address chronic diseases
Cardiovascular Optimization and Community Hub (COACH)
Cardiovascular Optimization and Community Hub (COACH)
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Equine asthma: Recognizing and managing respiratory issues in horses
Equine asthma: Recognizing and managing respiratory issues in horses
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications1,2
New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications1,2